Status:
RECRUITING
Quantitative Susceptibility Biomarker and Brain Structural Property for Cerebral Cavernous Malformation Related Epilepsy
Lead Sponsor:
yuanli Zhao
Collaborating Sponsors:
Peking University International Hospital
Conditions:
Cavernous Malformation, Cerebral
Cavernous Angioma
Eligibility:
All Genders
18-70 years
Brief Summary
Cerebral cavernous malformation (CCM)-related epilepsy (CRE) impairs the quality of life in patients with CCM. Patients could not always achieve seizure freedom after surgical resection of the lesion,...
Detailed Description
The CRESS study is a prospective observational study of imaging biomarker for cerebral cavernous malformation (CCM) related epilepsy (CRE) risk in natural history or after surgical resection. This pro...
Eligibility Criteria
Inclusion
- (1) 18 to 70 years of age
- (2) Diagnosed with a single cerebral cavernous malformation
- (3) No prior treatment of the symptomatic lesion
Exclusion
- (1) Associated with brain lesions and/or tumors other than CCM
- (2) History of previous intracranial surgery
- (3) Prior brain irradiation
- (4) Contraindication or unwilling or unable to undergo research MRI studies
- (5) Pregnant or breastfeeding women
- (6) Persons unable or unlikely to return for follow-up visits
- (7) Dementia or other progressive neurological disease
Key Trial Info
Start Date :
September 3 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2026
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT04076449
Start Date
September 3 2019
End Date
December 31 2026
Last Update
September 4 2019
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Beijing Tiantan Hospital, Capital Medical University
Beijing, Beijing Municipality, China, 100079
2
Peking University International Hospital
Beijing, Beijing Municipality, China, 102206